Advertisement

Topics

Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna

2015-05-20 20:55:42 | BioPortfolio

Published on BioPortfolio: 2015-05-20T20:55:42-0400

Clinical Trials [81 Associated Clinical Trials listed on BioPortfolio]

Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream

This study investigates the efficacy of photodynamic therapy (PDT) in the treatment of lentigo maligna (LM). Hyperspectral imaging system (HIS) will be used to determine the margins of LM ...

Prospective Study of Ingenol Mebutate for Non-invasive Lentigo Melanoma of the Face

Non-invasive lentigo maligna (LM) is characterized by an in situ proliferation of melanoma cells, limited to the epidermis. It is found most commonly on the head and neck of elderly person...

Mohs and Immunofluorescence for Malignant Melanoma In Situ

The purpose of this study is to determine if immunofluorescence (IF) can effectively identify features of malignant melanoma in situ, on sun-damaged skin, in the setting of Mohs Micrograph...

Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis

At the end of the study, safety and efficacy outcome measures will be compared to determine a) if dosing with Generic Imiquimod cream, 5% is therapeutically equivalent to the currently mar...

Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1

The purpose of this study is to determine if imiquimod cream can reverse the growth of neurofibromas. Imiquimod is a skin cream that works by stimulating the body's immune system to respo...

PubMed Articles [45 Associated PubMed Articles listed on BioPortfolio]

Lymphoedema in Lentigo Maligna patients treated with imiquimod, a long term adverse effect.

Lentigo Maligna (LM) is a potential precursor lesion of Lentigo Maligna Melanoma (LMM). It is treated to prevent progression to LMM. A recent epidemiological study reports a progression rate of 2.0-2....

Synchronous conjunctival melanoma and lentigo maligna melanoma.

Lentigo maligna has an extensive and neoplastic character. It typically progresses slowly and may eventually develop into an invasive melanoma, which is called lentigo maligna melanoma. Ocular melanom...

Correlation of Handheld Reflectance Confocal Microscopy With Radial Video Mosaicing for Margin Mapping of Lentigo Maligna and Lentigo Maligna Melanoma.

The management of lentigo maligna (LM) and LM melanoma (LMM) is challenging because of extensive subclinical spread and its occurrence on cosmetically sensitive areas. Reflectance confocal microscopy ...

Comparison of Melanocyte Density Counts in Topical Imiquimod-Treated Skin Surrounding Lentigo Maligna vs Control Biopsy Specimens.

In vivo reflectance confocal microscopy combined with the "spaghetti technique" for the identification of surgical margins of lentigo maligna: experience in 70 patients.

Lentigo maligna (LM) and lentigo maligna melanoma (LMM) account for 10% of all melanomas and are mainly located on head and neck areas.Complete surgical excision is the recommended treatment. However,...

Medical and Biotech [MESH] Definitions

Small circumscribed melanoses resembling, but differing histologically from, freckles. The concept includes senile lentigo ('liver spots') and nevoid lentigo (nevus spilus, lentigo simplex) and may also occur in association with multiple congenital defects or congenital syndromes (e.g., Peutz-Jeghers syndrome).

A cellular subtype of malignant melanoma. It is a pigmented lesion composed of melanocytes occurring on sun-exposed skin, usually the face and neck. The melanocytes are commonly multinucleated with a "starburst" appearance. It is considered by many to be the in situ phase of lentigo maligna melanoma.

A pattern recognition receptor that binds several forms of imidazo-quinoline including the antiviral compound Imiquimod.

An autosomal dominant disorder with an acronym of its seven features (LENTIGO; ELECTROCARDIOGRAM abnormalities; ocular HYPERTELORISM; PULMONARY STENOSIS; abnormal genitalia; retardation of growth; and DEAFNESS or SENSORINEURAL HEARING LOSS). This syndrome is caused by mutations of PTPN11 gene encoding the non-receptor PROTEIN TYROSINE PHOSPHATASE, type 11, and is an allelic to NOONAN SYNDROME. Features of LEOPARD syndrome overlap with those of NEUROFIBROMATOSIS 1 which is caused by mutations in the NEUROFIBROMATOSIS 1 GENES.

A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)

More From BioPortfolio on "Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial